| Literature DB >> 29063030 |
Xue-Li Yang1, Ji-Chun Chen1, Jian-Xin Li1, Jie Cao1, Xiang-Feng Lu1, Fang-Chao Liu1, Dong-Sheng Hu2, Xiao-Qing Liu3, Chong Shen4, Ling Yu5, Fang-Hong Lu6, Xian-Ping Wu7, Lian-Cheng Zhao1, Jian-Feng Huang1, Ying Li1, Xi-Gui Wu1, Dong-Feng Gu1.
Abstract
OBJECTIVE: This study aims to determine the distribution of observed atherosclerotic cardiovascular disease (ASCVD) incidence in contemporary cohorts in China, and to identify cut-off points for ASCVD risk classification based on traditional criteria and new equations developed by Prediction for ASCVD Risk in China (China-PAR).Entities:
Keywords: Atherosclerotic cardiovascular disease; China-PAR project; Cohort; Risk stratification
Year: 2016 PMID: 29063030 PMCID: PMC5643596 DOI: 10.1016/j.cdtm.2016.10.001
Source DB: PubMed Journal: Chronic Dis Transl Med ISSN: 2095-882X
Baseline characteristics of 34,757 subjects in cohorts from the China-PAR project.
| Risk groups | Very low | Low | Moderate | High | Very high |
|---|---|---|---|---|---|
| Sample size, | 6018 | 16,922 | 7303 | 3813 | 701 |
| Age, years | 43.72 (6.57) | 46.58 (7.96) | 50.54 (8.86) | 53.28 (9.45) | 53.23 (8.63) |
| Male, | 1066 (17.71) | 8332 (49.24) | 4121 (56.43) | 2506 (65.72) | 379 (54.07) |
| BMI, kg/m2 | 21.59 (2.41) | 22.55 (3.14) | 24.14 (3.68) | 25.76 (3.90) | 25.65 (4.26) |
| WC, cm | 71.21 (6.45) | 75.74 (8.32) | 80.98 (9.96) | 86.85 (10.31) | 85.08 (11.17) |
| SBP, mmHg | 112.33 (11.42) | 116.27 (12.24) | 132.68 (19.59) | 142.71 (14.44) | 184.24 (19.11) |
| DBP, mmHg | 72.57 (8.09) | 75.02 (8.39) | 83.89 (11.40) | 88.46 (9.42) | 107.95 (12.36) |
| Current smoker, | 0 (0.00) | 6078 (35.92) | 3120 (42.72) | 2040 (53.50) | 268 (38.23) |
| TC, mg/dl | 162.78 (22.37) | 182.16 (37.56) | 192.05 (39.91) | 202.79 (41.03) | 198.47 (43.59) |
| LDL-C, mg/dl | 91.28 (19.89) | 109.51 (33.06) | 116.41 (35.36) | 123.80 (36.15) | 122.44 (40.73) |
| HDL-C, mg/dl | 56.00 (10.88) | 52.03 (13.54) | 49.60 (13.89) | 46.83 (13.55) | 49.51 (13.61) |
| TG, mg/dl | 80.90 (65.00, 102.95) | 104.60 (77.70, 145.00) | 125.20 (90.00, 177.60) | 151.80 (106.60, 212.50) | 135.80 (97.30, 188.00) |
| Fasting plasma glucose, mg/dl | 83.08 (10.60) | 87.34 (12.58) | 99.29 (32.63) | 112.80 (41.81) | 102.94 (34.66) |
| Diabetes, | 0 (0.00) | 0 (0.00) | 637 (8.72) | 759 (19.91) | 88 (12.55) |
| Family history of ASCVD, | 0 (0.00) | 2336 (13.80) | 1587 (21.73) | 1095 (28.72) | 158 (22.54) |
Data were presented as means with standard derivation or the number of participants with percentages.
ASCVD: atherosclerotic cardiovascular disease; China-PAR project: Prediction for ASCVD Risk in China project; BMI: body mass index; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride.
Risk groups based on Chinese Guideline on Prevention of CVD in 2011.
TG, median with interquartile range.
Kaplan–Meier-adjusted 10-year ASCVD risk in 34,757 subjects in cohorts from the China-PAR project.
| Risk groups | Kaplan–Meier adjusted 10-year risk of ASCVD, % | |||
|---|---|---|---|---|
| Men (95% | Women (95% | |||
| Age, years | <0.001 | <0.001 | ||
| 35–44 | 1.63 (1.33, 1.93) | 0.89 (0.68, 1.10) | ||
| 45–54 | 3.98 (3.47, 4.49) | 2.38 (2.00, 2.76) | ||
| 55–64 | 8.39 (7.38, 9.40) | 5.23 (4.46, 6.00) | ||
| 65–74 | 13.22 (10.49.15.94) | 10.65 (8.15, 13.16) | ||
| Area | 0.05 | 0.42 | ||
| Urban | 4.18 (3.68, 4.67) | 2.54 (2.16, 2.92) | ||
| Rural | 4.03 (3.64, 4.41) | 2.46 (2.18, 2.75) | ||
| Geographic region | <0.001 | <0.001 | ||
| Northern | 5.40 (4.89, 5.90) | 3.64 (3.25, 4.04) | ||
| Southern | 2.90 (2.54, 3.26) | 1.43 (1.19, 1.67) | ||
ASCVD: atherosclerotic cardiovascular disease; China-PAR project: Prediction for ASCVD Risk in China project.
P-value, log-rank tests for 10-year risk of ASCVD across subgroups.
Ten-year ASCVD risk after Kaplan–Meier-adjustment across different groups for risk stratification.
| Risk groups | Sample size, | Kaplan–Meier adjusted 10-year ASCVD risk, % | ||
|---|---|---|---|---|
| All (95% | Men (95% | Women (95% | ||
| Very low | 6018 | 0.61 (0.41, 0.81) | 0.68 (0.18, 1.18) | 0.60 (0.38, 0.82) |
| Low | 16,922 | 1.63 (1.44, 1.82) | 1.80 (1.51, 2.09) | 1.46 (1.20, 1.72) |
| Moderate | 7303 | 4.61 (4.11, 5.10) | 4.65 (3.98, 5.31) | 4.55 (3.81, 5.29) |
| High | 3813 | 8.74 (7.82, 9.66) | 9.14 (7.98, 10.30) | 7.98 (6.47, 9.49) |
| Very high | 701 | 23.29 (20.06, 26.51) | 27.92 (23.25, 32.59) | 17.88 (13.59, 22.18) |
| Total | 34,757 | 3.25 (3.06, 3.44) | 4.13 (3.82, 4.44) | 2.49 (2.26, 2.72) |
ASCVD: atherosclerotic cardiovascular disease.
Fig. 1Incidence of ASCVD across different risk stratification groups. The 3 solid lines show the incidence of ASCVD based on the Chinese Guideline on Prevention of CVD, with the very low and low group as the green line, the moderate group as the blue line, and the high and very high group as the red line. The 3 dashed lines show the incidence of ASCVD based on the cut-off points from the China-PAR equations, with green, blue, and red dashed lines for <5%, 5–10%, and ≥10%, respectively. ASCVD: atherosclerotic cardiovascular disease. China-PAR project: Prediction for ASCVD Risk in China project.
Fig. 2Ten-year Kaplan–Meier observed and predicted ASCVD event rates among 34,757 participants in the cohorts from the China-PAR Project. The observed ASCVD rates after Kaplan–Meier-adjustment are shown as white bars, and the predicted ASCVD rates using the China-PAR equations are shown as black bars. ASCVD: atherosclerotic cardiovascular disease; China-PAR: Prediction for ASCVD Risk in China.